Literature DB >> 1637680

In vivo measurement of the association constant of a radio-labelled monoclonal antibody in experimental immunotargeting.

J G Fjeld1, H B Benestad, T Stigbrand, K Nustad.   

Abstract

Exploring the fundamental mechanisms behind the low tumour uptake of labelled monoclonal antibodies (MoAbs) during in vivo immunotargeting, experiments were performed to estimate the in vivo value of the association constant (Ka) in an experimental targeting reaction. An artificial tumour model was utilised, based on diffusion chambers (DC) filled with antigen-coated polymer particles, implanted i.p. in normal, immunocompetent mice (NMRI/BOM). The MoAb H7 with specificity for placental alkaline phosphatase (PLALP) was chosen for this experiment. Each mouse carried two DC, one target DC filled with PLALP-coated particles, and a second control DC with the same amount of uncoated particles. The DC contained escalating doses of particles, ranging from 0.1 mg to 16 mg per DC, with groups of 6-12 animals per dose level. The next day after the implantation, a constant dose of 125I-labelled Fab fragments of H7 was injected i.v. in each mouse. The association constant Ka as measured from the binding data obtained in vivo was not significantly different from the value measured in vitro when the same target DC were incubated with the 125I-Fab in test tubes. This indicates that in vivo impairment of the antibody avidity is not the reason why a relatively low tumour uptake is generally experienced in immunotargeting studies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1637680      PMCID: PMC1977891          DOI: 10.1038/bjc.1992.219

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  10 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

Review 2.  Delivery of novel therapeutic agents in tumors: physiological barriers and strategies.

Authors:  R K Jain
Journal:  J Natl Cancer Inst       Date:  1989-04-19       Impact factor: 13.506

3.  In vivo evaluation of radiolabelled antibodies with antigen-coated polymer particles in diffusion chambers.

Authors:  J G Fjeld; H B Benestad; T Stigbrand; K Nustad
Journal:  J Immunol Methods       Date:  1988-04-22       Impact factor: 2.303

4.  Diffusion chamber culturing of haematopoietic cells: methodological investigations and improvement of the technique.

Authors:  H B Benestad; A Reikvam
Journal:  Exp Hematol       Date:  1975-08       Impact factor: 3.084

5.  Hydrophilic monodisperse particles as solid-phase material in immunoassays: comparison of shell-and-core particles with compact particles.

Authors:  K Nustad; L Johansen; J Ugelstad; T Ellingsen; A Berge
Journal:  Eur Surg Res       Date:  1984       Impact factor: 1.745

6.  Antigenic determinants of human placental and testicular placental-like alkaline phosphatases as mapped by monoclonal antibodies.

Authors:  J L Millán; T Stigbrand
Journal:  Eur J Biochem       Date:  1983-10-17

7.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

8.  Immunoreactivity of monoclonal anti-melanoma antibodies in relation to the amount of radioactive iodine substituted to the antibody molecule.

Authors:  S Matzku; H Kirchgessner; W G Dippold; J Brüggen
Journal:  Eur J Nucl Med       Date:  1985

Review 9.  Monoclonal antibodies for imaging and therapy.

Authors:  A A Epenetos; C Kosmas
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

10.  Radioimmunotargeting of human tumour cells in immunocompetent animals.

Authors:  J G Fjeld; O S Bruland; H B Benestad; L Schjerven; T Stigbrand; K Nustad
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.